# TOP 2301: Neoadjuvant Chemo for NSCLC

> **NCT06385262** · PHASE2 · SUSPENDED · sponsor: **Duke University** · enrollment: 126 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Cemiplimab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06385262
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-03-17
- **Primary completion:** 2028-10-30
- **Final completion:** 2029-10-30
- **Target enrollment:** 126 (ESTIMATED)
- **Why stopped:** Protocol is currently undergoing study design revisions and will re-open after amendment is IRB approved
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06385262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06385262, "TOP 2301: Neoadjuvant Chemo for NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06385262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*